The Laboratory Animal Shared Resource (LAR) provides the entire spectrum of animal-related research services, including specialized veterinary medical care, expert animal husbandry, diagnostic and surgical services, imaging resources and training of investigators and laboratory personnel. The LAR promotes the humane care and use of laboratory animals in support of basic and translational research. Although the majority of animal care services provided by LAR are related to mice and rats, the animal program at RPCI has been expanded to include larger species including rabbits, woodchucks, dogs and pigs. Two buildings are designated for the LAR. The main site is the four-story 45,000 net square foot (nsf) Vivarium, which opened in 1998, located in the Medical Research Complex. An additional 5,000 nsf is utilized in the adjacent Cancer Cell Center. The LAR Facility Director and Attending Veterinarian, Sandra (Buitrago) Sexton DVM, oversees the Veterinary Program to a standard that ensures that all services meet or exceed the criteria set in the LAR's AAALAC accreditation. She is assisted by a qualified support staff for administration and management of the facility and for provision of specialized veterinary medical care. Dr. Sexton provides training and education programs for researchers on proper care and use of animals, including: Clinical care of laboratory animals (proper handling, postoperative care, analgesia and surgery techniques) A preventive animal health-monitoring program Coordination of import/export of animals to and from other facilities, promoting a strong collaborative relationship with scientists and clinicians at other institutions with major focus in cancer research. A total of 46 staff members comprise the LAR workforce, with CCSG direct effort of 5.86 FTE. Continued support through the NCI permits the Resource to provide a standard of animal care that exceeds applicable state and federal regulations, maintains full AAALAC International accreditation, and furnishes investigators with a comprehensive program for safe, appropriate and cost-effective research animal use. Prioritization for Resource utilization is 1) peer-review-funded CCSG members;2) non-peer-review-funded CCSG members; 3) non-members and academic collaborators;and 4) external users. During the reporting period, the Laboratory Animal Shared Resource has served 83 members from 6 research programs, with 72% utilization by CCSG members with peer reviewed funding. The CCSG support provides 4% of the overall proposed budget.

Public Health Relevance

All transitional research requires pre-clinical testing using laboratory animals prior to moving to clinical trials with humans. New faculty members have been recruited by the Institute to enhance its excellence in basic, translational and cancer research programs, contributing to an increased demand for the LAR. These positive developments have contributed to scientific and clinical growth at the cancer center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-37
Application #
8738384
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-06-16
Project End
2019-04-30
Budget Start
2014-06-26
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$203,358
Indirect Cost
$80,436
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Nesher, Elimelech; Safina, Alfiya; Aljahdali, Ieman et al. (2018) Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. Cancer Res 78:1431-1443
Verma, Aparajita; Rich, Laurie J; Vincent-Chong, Vui King et al. (2018) Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer. J Oral Pathol Med 47:484-491
Sheffer, Christine E; Miller, Austin; Bickel, Warren K et al. (2018) The treasure of now and an uncertain future: Delay discounting and health behaviors among cancer survivors. Cancer 124:4711-4719
Szender, J Brian; Kaur, Jasmine; Clayback, Katherine et al. (2018) Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer. Int J Gynecol Cancer 28:26-33
Azad, T; Janse van Rensburg, H J; Lightbody, E D et al. (2018) A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis. Nat Commun 9:1061
Buas, Matthew F; Li, Christopher I; Anderson, Garnet L et al. (2018) Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values. Cancer Epidemiol 56:83-89
Chung, Sejin; Vail, Paris J; Witkiewicz, Agnieszka K et al. (2018) Coordinately targeting cell cycle checkpoint functions in integrated models of pancreatic cancer. Clin Cancer Res :
Eng, Diana G; Kaverina, Natalya V; Schneider, Remington R S et al. (2018) Detection of renin lineage cell transdifferentiation to podocytes in the kidney glomerulus with dual lineage tracing. Kidney Int 93:1240-1246
Ling, Xiang; Wu, Wenjie; Fan, Chuandong et al. (2018) An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. J Exp Clin Cancer Res 37:240
Sandlesh, Poorva; Juang, Thierry; Safina, Alfiya et al. (2018) Uncovering the fine print of the CreERT2-LoxP system while generating a conditional knockout mouse model of Ssrp1 gene. PLoS One 13:e0199785

Showing the most recent 10 out of 1555 publications